Actively Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Led by CRISPR Therapeutics AG · Updated on 2025-11-14
120
Participants Needed
7
Research Sites
360 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
CONDITIONS
Official Title
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Relapsed or refractory B cell malignancy
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Adequate kidney, liver, heart, and lung function
- Agreement to use acceptable contraception methods during the study and for 12 months after CTX112 infusion (for females of childbearing potential and males)
You will not qualify if you...
- Prior allogeneic hematopoietic stem cell transplant
- Active or past involvement of the central nervous system by malignancy
- History of seizure disorder, stroke, dementia, cerebellar disease, or autoimmune diseases affecting the central nervous system
- Uncontrolled bacterial, viral, or fungal infection requiring intravenous treatment
- Active infection with HIV, hepatitis B, or hepatitis C viruses
- Previous or concurrent cancer within the last 3 years, except non-melanoma skin cancer or cancers with low risk of recurrence
- Use of systemic anticancer biologic drugs within 30 days or non-biologic anticancer drugs within 14 days before CTX112 infusion
- Primary immunodeficiency or autoimmune disease requiring steroids or immunosuppressive therapy
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
University of Kansas
Westwood, Kansas, United States, 66205
Actively Recruiting
2
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
3
SCRI
San Antonio, Texas, United States, 78229
Actively Recruiting
4
University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
5
Royal Prince Alfred
Camperdown, New South Wales, Australia, 2050
Actively Recruiting
6
Alfred Health
Melbourne, Victoria, Australia, 3004
Actively Recruiting
7
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
Research Team
C
Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here